Zimbabwe has turned down a significant American health deal worth 367 million US dollars (272 million pounds) over five years because of Washington's request for sensitive biological samples.
This rejection became public after a internal memorandum from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government representative has since stated that the US was requesting biological samples for research and commercial gain while was unwilling to guarantee the resulting advantages from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for continued negotiations to find a agreement acceptable to both sides so the country's vital HIV programme can be sustained.
Broader Implications
Zimbabwe's decision follows a comparable case in Kenya, where a court halted a related health funding agreement after legal challenges were filed about the security of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump stated its spending was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and responsibility.
According to statements, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million currently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to provide its biological resources and data over an extended period, without any equivalent guarantee of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a future pandemic arise."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining systems previously set up via the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage potential global health emergencies.
"This mechanism is designed to ensure that when a nation contributes its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to develop them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage further discussions with our US partners on how future collaboration could be designed in a manner that honours the independence and interests of both nations."
Medical Community Response
Medical experts said it acknowledged the official position, but urged that talks need to persist since a large portion of the country's HIV programmes depended on international support.
"If technical issues exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
This impasse emphasises the ongoing challenges between accepting much-needed international aid and protecting a country's data in an ever more data-driven world.